{"id":867790,"date":"2025-07-09T08:07:11","date_gmt":"2025-07-09T12:07:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/"},"modified":"2025-07-09T08:07:11","modified_gmt":"2025-07-09T12:07:11","slug":"briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/","title":{"rendered":"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell\u2019s Bria-OTS in Phase 1\/2a study<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>No treatment limited toxicities observed<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Patient remains on study with stable disease elsewhere<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">\n        <br \/>PHILADELPHIA and VANCOUVER, British Columbia, July  09, 2025  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company\u2019s personalized off the shelf immunotherapy.<\/p>\n<p align=\"justify\">BriaCell\u2019s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis following four doses of BriaCell\u2019s Bria-OTS monotherapy. The complete response was first observed at two months (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l4LgELIc29IpKqJ7Ss2DrehitBSVvCC5-wqq3YVuzrDz0ulpEM9pRtsKOtDEc9kc1ppj4G96K-khnIJistGkEKs-nG-lAmqyhmyGOBaexbRea6uhHd71sQGxC_J2FTql9EDcmtXvNvhBiwze_JJ2UDP9TuIvEoldWOoBt-cu1yM1OaVc9FQB0lUkVJN3nU2-\" rel=\"nofollow\" target=\"_blank\">previously reported<\/a>) and confirmed at four (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l4LgELIc29IpKqJ7Ss2DrVDQpobEwEaySBjinpkDrZ9v1hpCaP8Rkvja2ZQHZrs9VyjVgSzU5idWpgiosOXV8-ZTiEt370Iw4B3v_f7yFM8NaqrBhg_2Qr_FUT9PLfsFkwMP6wFr4mGtggwRT6I_JYOse6QM-DfRvedr0Cfp2io1URHc3sz1AL0B1SexvmsO\" rel=\"nofollow\" target=\"_blank\">previously reported<\/a>) and now six months. The patient has been dosed with 12 cycles of Bria-OTS to date.<\/p>\n<p align=\"left\">\n        <strong>Figure 1: Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the right lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4, and 6 months of therapy<\/strong><br \/>\n        <sup><br \/>\n          <strong>1<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> (axial and coronal views)<\/p>\n<p><\/strong>\n      <\/p>\n<p align=\"justify\">\n        \n      <\/p>\n<p align=\"justify\">\u201cThese results represent an exciting clinical milestone in the Bria-OTS program,\u201d stated Neal S. Chawla MD, Director at the Sarcoma Oncology Center, Santa Monica, CA, and Principal Investigator for the Bria-OTS study. \u201cWe are seeing strong single agent activity in a very challenging population and are eager to explore this approach across more patient subtypes and tumors.\u201d<\/p>\n<p align=\"justify\">\u201cWe are highly encouraged by this remarkable and durable clinical response, especially at the lowest dose level,\u201d added Dr. William V. Williams, BriaCell\u2019s President and CEO. \u201cThis data underscores the therapeutic potential of our Bria-OTS platform, and we look forward to further evaluating it in combination with a checkpoint inhibitor to improve outcomes in patients with advanced breast cancer.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Bria-OTS<\/strong>\n      <\/p>\n<p align=\"justify\">Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell\u2019s lead candidate Bria-IMT currently being evaluated in a Phase 1\/2a study (ClinicalTrials.gov identifier: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cRYV7kWNiBu782DqfIWXJxJgrp3Le9l0pglifYkAEan0SRbRmwZTdF5XevdFDabeK3v3_GCHtbbFh6FD9lQZUNMfnT8tvPxhbgozGOoHiyHwTo5n9L7UWcTZ7eZ1vM7A4PBjPk2E4-s81AVMS_-EXA==\" rel=\"nofollow\" target=\"_blank\">NCT06471673<\/a>) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and check point inhibition combination dose expansion cohorts. The Company recently progressed into the dose expansion phase.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j635rKZctvy9ylDt3_hkTTubu0aP2N3dxoH2FjvT3nkpLIiCqFzaMIva-TbRnoG3OEkagKke2uGm1eoDqwJUOddeMnVwDmQakWlYMI5dxxs=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release include statements regarding: BriaCell continuing the Phase 1\/2a Bria-OTS study and reproducing similar results in patients with MBC and other cancers; the use of the Bria-OTS platform as monotherapy; and Bria-OTS\u2019s validation as a personalized immunotherapy approach. Forward-looking statements may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xiqtGoLFVaLVDodGKLFImstqCs2hCFbBKKIsr429wr4IcwtuA7uaKDSplEIpYenJH_tqDpmFZeKak5Ycbu8gGmq9v5P7r6sOwa5AwfU2ByFGgn38wMKWIzCtm6EhlH3pPbsqJ68tNCD9W4kueVXIB1iVabPy961MhDvHjudkpmgp5goB-Z2dJtT-vz4Lmlg-bs0kzdfd-Yb5140frtk-VK1ddMg942Nw-49NC43_h9g=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca<\/strong><\/a><strong>\u00a0<\/strong>and on EDGAR at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xiqtGoLFVaLVDodGKLFImjZwwpGYZQ1dF1rQkEa1Fqdfgyx-IJk4PWm6BfsxJwTP4mp9fd8g1vdiH4qg-dBRz5K_N2lgIVWnUe970aFFZiGs2B7qAl0G5YZ7goudwLonUZM7BgAWquiT5TOTvDg1TvRAUdGlk00BNZ36cYBpid7gHXLZO3P2Y8RpHKhkC1GDMDV4-SlmjRQqJkFbxCUmDd5za7wNn7Zmj5IxV1x7JH8=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-PysVyEstWLq1yG9TpdjASJD-Q5oHBmH9e5rBXlM8m67pVnYEfduppy4ogqgYwEmVrL7ih40O9Luas-YTK0-qtbzvsdEfNeJ56Jp6cjqTtY=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UnvK8kkJK0AdRlFdJEFB_hHR-0rCp2HGVzQuGFQgBmb6pWwVey8LSuQRG603FzVMjgdK_DWSSzCEdT_ELI9r4QkiXf4rfgPvIpG5paEGIM4=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p align=\"justify\">\n        <sup>1<\/sup> Note that the other white dots in the lungs are blood vessels.<\/p>\n<p align=\"justify\">A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j635rKZctvy9ylDt3_hkTWwtZw8FhAU2-NYsktCm2alvxnYQJqfWS8S07Y4ZKxViXxSfyaUP93Rq9Xn1-go8_upK0eUIquoUweSScVZsbjTehupXZdwT3WxS0Evd2quWJs0VQAJJLCoX0OK7Uk2WsvTBukH6-6GCB2J45eQ983w4mfXjmcWajC5Kx7TzUEP011_4H7J1xHXxvfP9hvaGbPgDl8O01CEH5wf01KmL6vxBVXZFovaCtWIl5XpGpXn6c9dlQOenrBss52YqWgX5Xw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/086d3bd1-2e71-468f-9d93-f7ebafff2797<\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Mzg4ZDI4YzctYTczMS00M2QyLTgyNTItOGEwOGYyNjBjNjFmLTExMDIyMjktMjAyNS0wNy0wOS1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell\u2019s Bria-OTS in Phase 1\/2a study No treatment limited toxicities observed Patient remains on study with stable disease elsewhere PHILADELPHIA and VANCOUVER, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company\u2019s personalized off the shelf immunotherapy. BriaCell\u2019s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-867790","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell\u2019s Bria-OTS in Phase 1\/2a study No treatment limited toxicities observed Patient remains on study with stable disease elsewhere PHILADELPHIA and VANCOUVER, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company\u2019s personalized off the shelf immunotherapy. BriaCell\u2019s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung &hellip; Continue reading &quot;BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T12:07:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study\",\"datePublished\":\"2025-07-09T12:07:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/\"},\"wordCount\":768,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/\",\"name\":\"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=\",\"datePublished\":\"2025-07-09T12:07:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study - Market Newsdesk","og_description":"[IMAGES BELOW] Complete resolution maintained at 6 months in first patient treated with BriaCell\u2019s Bria-OTS in Phase 1\/2a study No treatment limited toxicities observed Patient remains on study with stable disease elsewhere PHILADELPHIA and VANCOUVER, British Columbia, July 09, 2025 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the sustained complete resolution of lung metastasis in a patient with hormone receptor-positive (HR+), HER2-negative, metastatic breast cancer (MBC) treated with Bria-OTS, the Company\u2019s personalized off the shelf immunotherapy. BriaCell\u2019s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung &hellip; Continue reading \"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-09T12:07:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study","datePublished":"2025-07-09T12:07:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/"},"wordCount":768,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/","name":"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=","datePublished":"2025-07-09T12:07:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTM2NyM3MDM4NjQzIzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS\u2122 Metastatic Breast Cancer Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/867790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=867790"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/867790\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=867790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=867790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=867790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}